<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739463</url>
  </required_header>
  <id_info>
    <org_study_id>MP-31-2018-2496</org_study_id>
    <nct_id>NCT03739463</nct_id>
  </id_info>
  <brief_title>Pro-omega-3, Reduction of Inflammation and Modulation of Prematurity</brief_title>
  <acronym>Pro-MEGA</acronym>
  <official_title>Pro-omega-3, Reduction of Inflammation and Modulation of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to decrease the inflammatory status of pregnant women with preterm
      premature rupture of membranes to delay the initiation of labour that would inevitably lead
      to premature delivery. The main objective is to measure the mean duration between the
      initiation of the treatment and delivery in the two groups treated either with MAG-DHA or
      with the placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled trial will be conducted in two hospitals in the province of Quebec
      (CHUS, CHUQ- Site mère-enfant Soleil).

      Patients between 24 and 33 weeks of gestation with a diagnosis of preterm premature rupture
      of membranes (PPROM) who meet all inclusion and none of the exclusion criteria will be
      approached to participate. Once they have signed the IFC, participants will be randomized and
      begin a supplementation with either MAG-DHA or the placebo until delivery or for up to 2
      weeks (14 days). A total of 70 patients will be recruited.

      Principal outcome: To compare the difference in duration between the start of treatment and
      delivery between the group receiving MAG-DHA and the group receiving placebo.

      Secondary outcomes: 1) Evaluate the difference in neonatal outcome between children in the
      MAG-DHA group and those in the placebo group. 2) Determine the inflammatory status of the
      patients associated with the exposure to either MAG-DHA or the placebo.

      This regimen could potentially represent an innovative approach in the management of women
      with a diagnosis of PPROM.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 3, 2018</start_date>
  <completion_date type="Anticipated">May 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration latency period</measure>
    <time_frame>From PPROM through delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal score</measure>
    <time_frame>From birth through the first 28 days of life</time_frame>
    <description>Composite neonatal score includes any one or more of the following: acute respiratory distress, bronchopulmonary dysplasia, proven sepsis, necrotizing enterocolitis, severe intraventricular hemorrhage (grade&gt; 2) or periventricular leukomalacia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory status</measure>
    <time_frame>Every 2-3 days from PPROM until delivery or a maximum of 14 days, whichever happens first</time_frame>
    <description>Inflammatory status will be determined based on the quantification of any one or more of the following biomarkers in blood and vaginal secretions specimens: resolvins, lipoxygenase isoforms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>PPROM</condition>
  <arm_group>
    <arm_group_label>MAG-DHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1500 MG of MAG-DHA per day until childbirth or for up to 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1500 MG of oleic acid per day until childbirth or for up to 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MAG-DHA</intervention_name>
    <description>375 MG of MAG-DHA per capsules, two capsules BID</description>
    <arm_group_label>MAG-DHA</arm_group_label>
    <other_name>Pro-omega-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oleic acid</intervention_name>
    <description>375 MG of sunflower oil (oleic acid) per capsules, two capsules BID</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sunflower oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PPROM diagnosis, gestational age between 24 and 33 weeks of gestation.

        Exclusion Criteria:

          -  multiple pregnancy, placenta previa, preeclampsia, retroplacental hematoma,
             chorioamnionitis, intrauterine growth retardation, severe fetal malformations
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnacy required</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Rousseau, PhD</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>75306</phone_ext>
    <email>eric-rousseau@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Belle Poirier, PhD</last_name>
    <phone>8193461110</phone>
    <phone_ext>12865</phone_ext>
    <email>Marie-Belle.Poirier@USherbrooke.ca</email>
  </overall_contact_backup>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pro-omega-3</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Prematurity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

